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ABSTRACT
Dendritic cells (DCs) are important immune cells linking
innate and adaptive immune responses. DCs encounter
various self and non-self antigens present in the envi-
ronment and induce different types of antigen speciﬁc
adaptive immune responses. DCs can be classiﬁed into
lymphoid tissue-resident DCs, migratory DCs, non-lym-
phoid resident DCs, and monocyte derived DCs
(moDCs). Recent work has also established that DCs
consist of developmentally and functionally distinct
subsets that differentially regulate T lymphocyte func-
tion. The development of different DC subsets has been
found to be regulated by a network of different cytokines
and transcriptional factors. Moreover, the response of
DC is tightly regulated to maintain the homeostasis of
immune system. MicroRNAs (miRNAs) are an important
class of cellular regulators that modulate gene expres-
sion and thereby inﬂuence cell fate and function. In the
immune system, miRNAs act at checkpoints during
hematopoietic development and cell subset differentia-
tion, they modulate effector cell function, and are
implicated in the maintenance of homeostasis. DCs are
also regulated by miRNAs. In the past decade, much
progress has been made to understand the role of
miRNAs in regulating the development and function of
DCs. In this review, we summarize the origin and dis-
tribution of different mouse DC subsets in both lym-
phoid and non-lymphoid tissues. The DC subsets
identiﬁed in human are also described. Recent progress
on the function of miRNAs in the development and
activation of DCs and their functional relevance to
autoimmune diseases are discussed.
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development, autoimmune disease
INTRODUCTION
DCs were discovered by Ralph Steinman and Zanvil Cohn in
the late 1970s, while the notion that DCs have a unique role
in the immune system was met with decades of skepticism
(Steinman and Cohn, 1973; Steinman and Cohn, 1974).
Forty years later, the exquisite ability of DCs to mount
adaptive immune responses to foreign antigens is gradually
recognized, and their contribution to the induction of toler-
ance to self-antigens is also becoming increasingly evident.
Consequently, the potential therapeutic beneﬁts of modu-
lating the development and functions of DCs for vaccines
against pathogens, tumors, and suppressive therapies for
autoimmune diseases have attracted more attention in the
research and clinical applications.
In the mid-1990s, the full scope and signiﬁcance of DC
diversity was ﬁrst acknowledged. The ﬁnding that the DCs in
murine spleen include two subsets deﬁned by the presence or
absence of CD8 expression and with distinct immune func-
tions, substantially broadened our knowledge of the roles of
DCs in the induction of adaptive immunity (Shortman and
Heath, 2010). However, theexistenceof distinct DCsubsets in
non-lymphoid tissues was recognized much later. This was
mainly due to the fact that although the functionally equivalent
DC subsets shared several phenotypic features with their
counterparts in lymphoid tissues, they did not, in fact, express
CD8. Nevertheless, theywere eventually characterized by the
expression of the integrin CD103 (Helft et al., 2010).
Moreover, another major subset of the DC family was
identiﬁed as a population of cells morphologically resembled
plasma cells with weak antigen presentation ability, but,
upon exposure to viral stimuli, they can produce large
amounts of type-I interferon. In addition, upon viral stimula-
tion these cells can also differentiate into immunogenic DCs
that can prime T cells against viral antigens. These cells
were named plasmacytoid DCs (pDCs) to distinguish them
from the conventional DCs (cDCs) (Colonna et al., 2004).











MicroRNAs (miRNAs) are small regulatory non-coding
RNAs that repress target transcripts post-transcriptionally.
Within the past decade, the role of microRNAs (miRNAs) in
immunology has been studied extensively. The importance of
miRNAs in the control of differentiation and function of
hematopoietic cells is clearly demonstrated by studies that
genetically disrupt critical enzymes important for the biosyn-
thesis of miRNAs (Xiao and Rajewsky, 2009). By gene tar-
geting, it has been shown that genetic deﬁciency of Drosha
results in the loss of maturemiRNAs. In hematopoietic cells, T
cell-speciﬁc Drosha and Dicer conditional knockout mice both
spontaneously develop lymphoproliferative multi-organ
inﬂammatory disease and die within a few weeks after birth
(Chong et al., 2008). While the earliest studies of miRNA
function in the immune system have demonstrated an
essential role for miRNAs as a whole, later studies have
focused on the contribution of speciﬁc miRNAs to speciﬁc
immunologic processes. The important roles of miRNAs in
hematopoietic development, cancer, immune homeostasis,
inﬂammatory disease, and autoimmunity were gradually
clariﬁed. Such roles include their ability to negatively regulate
signaling pathways and the expression of transcription factors
essential in lineage commitment. It has been shown that
development of speciﬁc cell lineages is often dependent on
speciﬁcmiRNAs.MiRNAs also play important roles in immune
tolerance and many immune-related miRNAs regulate cell
growth and apoptosis, leading to their high frequency of
association with hematologic malignancy (Mehta and Balti-
more, 2016). In this review, we will discuss the function of
miRNAs in regulating DC differentiation and functions and
their association with autoimmune diseases.
DC IN LYMPHOID TISSUES
DC in thymus
The thymus is a central immune organ and an important site
for T cell differentiation, selection and generation of naive
CD4+ and CD8+ T lymphocytes. Mouse thymus also con-
tains CD11cintCD45RA+ plasmacytoid DCs (pDCs) and two
CD11chiCD45RA− conventional DC (cDC) subsets that can
be segregated on the basis of CD8α and the signal regula-
tory protein-α (Sirp-α) expression, as CD8α+Sirp-α− and
CD8α−/loSirp-α+ cDC subsets (Fig. 1) (Lahoud et al., 2006;
Donskoy and Goldschneider, 2006). The CD8α+Sirp-α−
subset representing about 70% of thymic cDC is generated
within the thymus from the earliest intrathymic progenitors,
whereas the minor CD8α−/loSirp-α+ cDC subset originates
from the peripheral migratory DCs (Donskoy and Gold-
schneider, 2006). Thymic cDC, although sharing many
common features, differ from other peripheral DC subsets in
that the majority of thymic cDCs in mouse is derived from an
intrathymic precursor, and the former mostly present self-
antigens (Ag) rather than foreign Ag (Wu et al., 1995; Wu
et al., 1996). Thymic cDCs play important roles in the
induction of central immune tolerance through a process
called negative selection that deletes the developing thy-
mocytes with self-reactivity and the generation of the natu-
rally occurring CD4+CD25+ regulatory Tcells (Goldschneider
and Cone, 2003; Gallegos and Bevan, 2004; Watanabe
et al., 2005; Bonasio et al., 2006; Proietto et al., 2008).
Human thymus also contain DC subsets with similar func-
tions as those found in the mouse (Bendriss-Vermare et al.,
2001; Vandenabeele et al., 2001; Gurney et al., 2004; Keir
et al., 2002).
DC in spleen
Thespleen isa richsourceof lymphoid tissue-residentDCs.The
DC populations in mouse spleen have been well characterized
(Fig. 1). Three cDC subsets have been identiﬁed in the mouse
spleen based on the surface expression of CD8α and CD4, in
addition to high levels of CD11c expression on all cDCs. These
cDC subsets are CD11chiCD4−CD8α+, CD11chiCD4−CD8α−,
and CD11chiCD4+CD8α−. The CD4−CD8α+ cDCs also express
CD205, but not Sirp-α. In contrast, both CD4−CD8α− and
CD4+CD8α− cDC subsets do not express CD205−, but are
Sirp-α+, and are sometimes considered as one CD8α− cDC
subset (Lahoud et al., 2006; Vremec et al., 2000). The
CD8α−CD205− cDCsare located in themarginal zone,whereas
the CD8α+CD205+ cDCs are in Tcell areas. Marginal-zone DC
can rapidly migrate into the T cell zone upon activation (De
Smedt et al., 1996). A signiﬁcant number of splenic cDC can be
generated in situby the intrasplenic immediate cDCprecursors,
named pre-DCs (Naik et al., 2006; Diao et al., 2006).
In addition to cDCs, pDCs are also found in mouse spleen.
They are deﬁned as CD11cintCD45RA+B220+SiglecH+. Sim-
ilar to the blood pDC, the freshly isolated splenic pDC do not
have the phenotypic and functional features of the antigen-
presenting cDC, but can assume a cDC morphology and
upregulate the cDC markers CD11c and MHC class II after
activation with microbial stimuli. They represent the major cell
type that produce largeamounts of type-I interferon, a cytokine
involved in innate immunity to virus. The pDCs in spleen
migrate from the peripheral blood, because cells with the
characteristics of pDC can be found in mouse blood, and the
intrasplenic pre-DC do not differentiate into pDC (Asselin-
Paturel et al., 2001; Nakano et al., 2001; O’Keeffe et al., 2002;
O’Keeffe et al., 2003). Human spleen also contains pDCs,
displaying plasma cell morphology, that selectively express
Toll-like receptor (TLR)-7 and TLR9, and are specialized to
rapidly secret massive amounts of type 1 interferon following
viral stimulation. These are the CD4+CD11c−Lin−BDCA-2+
BDCA-4+ cells (Siegal et al., 1999; Kadowaki et al., 2001; Liu,
2005; Mittag et al., 2011).
DC in lymph node
The DC populations found in mouse LNs are more complex
(Fig. 1). In addition to the three phenotypically and func-
tionally equivalent cDC populations found in mouse spleen,
two additional subpopulations have been described in the
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skin draining LNs. These correspond to the mature
CD8αloCD205int and CD8αloCD205hi cDC that migrate from
the epidermis and dermis, respectively, to the LNs.
Subcutaneous LNs contain a higher percentage of the
CD8αloCD205hi Langerhans cell (LC)-like cells than
mesenteric LNs. The DCs derived from the migratory LC are
responsible for carrying antigens picked up from skin to the
draining LNs (Henri et al., 2001; Hochrein et al., 2001). In
human LN, HLA−DR+CD11c−BDCA4+ cells have been
identiﬁed as pDCs. HLA−DR+CD11c+ cells were separated
into CD14+ and CD1a+ cells, which can be further divided
into EpCAM+ LCs and CD1a+ DCs. CD1a−CD14− cells can
be further fractionated into Clec9A+ and BDCA1+ popula-
tions. Finally, BDCA1+ cells are comprised two subsets
which either do or do not express CD206. Similar analysis of
lymphoid organs that do not drain the skin showed that three
of these DC subsets (LCs, CD1a+, and CD206+ DCs) were
absent from cervical LNs draining the oropharynx, iliac LNs,
tonsils, and spleen, suggesting that these DCs in skin-
draining LNs are unique to and derived from the skin (Segura
et al., 2012).
ORIGINS OF LYMPHOID TISSUE DC
DCs, like all other leukocytes, develop from bone marrow-
derived hematopoietic stem cells. Both cDC and pDC can be
generated from the Flt3 expressing early myeloid or lymphoid
progenitors, and Flt3L is essential for the development of
steady-state DC populations (Fig. 2). When common lym-
phoid precursors (CLPs) and common myeloid precursors
(CMPs) were puriﬁed from mouse bone marrow (BM) and
adoptively transferred intravenously into irradiated recipient
mice, they both showed the potential to give rise to splenic
cDCs and pDCs. However, CMPs are 10-fold more abundant
thanCLPs; therefore,most spleen cDCsoriginate fromCMPs.
pDC are also derived from CMP, CLP, and DC restricted pre-
cursors CDP (common DC precursors) when these precur-
sors are transferred into irradiated recipients (Wu et al., 2001;
Manz et al., 2001; D’Amico andWu, 2003; Martín et al., 2000).
DC IN PERIPHERAL TISSUES
Non-lymphoid tissue-resident DCs are present in most tis-























Figure 1. DC subsets in the lymphoid and non-lymphoid tissues of mouse and human. Lymphoid tissues in mouse contain
pDC, CD8α+ cDC and CD4+ cDC, while lymphoid tissues in human contain pDC, CD141+ DC and CD1c+ DC. Mouse peripheral blood
contains pDC while human blood contains pDC, CD141+ DC and CD1c+ DC. Non-lymphoid tissues in mouse contain CD103+ DC and
CD11b+ DC, while non-lymphoid tissues in human contain CD141+ DC, CD1c+ DC and CD14+ DC.
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lack the expression of other hematopoietic cell lineage
markers, but express the hematopoietic speciﬁc marker
CD45, the integrin CD11c, and constitutively the major his-
tocompatibility complex class II (MHCII). Several studies
have now established that this deﬁnition is too broad and
includes distinct DC populations with different origins and
functions. Studies of non-lymphoid tissue DCs so far have
largely involved tissues that are in contact with the body
surfaces, such as the skin, lung, and intestine. We therefore
will focus our review on the DCs from these speciﬁc tissues.
DC in intestine
The intestine harbors a complex system of organized lym-
phoid tissues as primary sites for the induction of adaptive
mucosal immune responses, including ileal Peyer’s patches,
colonic isolated lymphoid follicles, and mesenteric lymph
nodes (MLNs). Due to the difﬁculty of obtaining normal
human gut tissues, most of the studies were done using
mouse models. Like other tissue cDCs, mouse intestinal
non-lymphoid tissue cDCs are Flt3L dependent and pre-DC
derived (Bogunovic et al., 2009; Varol et al., 2009; Schulz
et al., 2009; Edelson et al., 2010). Under steady-state, all
intestinal cDCs are migratory cells, arising from classic DC
precursors, without monocytic intermediates.
Intestinal DCs were originally deﬁned as CD11c+ cells
which were then subfractionated into intestinal macrophages
(now best deﬁned as CD11c+CD64+ cells) and DC
(MHCII+CD11c+CD64−) subsets. MHCII+CD11c+ DCs inclu-
ded subpopulations best characterized as CD103+CD11b−
and CD103+CD11b+ (Bogunovic et al., 2009; Varol et al.,
2009). The generation of intestinal CD103+CD11b− cDCs
depends on BATF3, Id2, and IRF8 and these cells thus
represent the gut equivalent of splenic CD8α+ cDCs (Edel-
son et al., 2010; Klebanoff et al., 2013). Intestinal
CD103+CD11b+ cDCs were subfractionated via the surface
markers CD24 and CD64, revealing their composition of
bona ﬁde Flt3-dependent CD24+CD64− cells and contami-
nating CD24−CD64+ cells that represent intestinal
macrophages.
The development of CD24+CD103+CD11b+ DCs depends
on transcription factor IRF4 (Persson et al., 2013), and the
presence of granulocyte-macrophage colony stimulating
factor (GM-CSF) is also required for the generation of
CD103+CD11b+ lamina propria (LP) DCs (Farache et al.,
2013). These CD103+CD11b+ LP DCs have been implicated
in both the maintenance of tolerance towards the commen-
sal microﬂora, and the generation of protective immune
responses against pathogens (Jaensson et al., 2008; Far-
ache et al., 2013). In the steady state, the functional prop-
erties of DCs appear to vary according to their anatomical
locations. Indeed, CD103+CD11b+ DCs are required in vivo
for efﬁcient generation of Treg cells (Scott et al., 2014;










Figure 2. The development of different DC subsets. All DC subsets are derived from Flt3+ LMPP. CD8α+ cDC, CD8α− cDC and
CD103+ DC originate from CMP and CDP. pDC are differentiated from CLP, CMP and CDP. Langerhans cells and moDC are from
monocytes.
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The lung, like the intestine, is vulnerable to pathogenic insult
and is constantly exposed to potentially harmful substances.
Studies have highlighted the abundance of DCs in lung tis-
sue and their dynamic accumulation upon stimulation. The
mouse lung is grossly divided into large conducting airways
and lung interstitium containing alveolar septa and capillar-
ies where gas exchange is taking place. Under steady-state
conditions, the conducting airways of all species studied are
lined with an intraepithelial highly dendritic network of
MHCIIhiCD11chi cells that are mostly CD11b− and express
langerin and the mucosal integrin CD103 (αEβ7) (Lambrecht
and Hammad, 2009).
In addition the network has the propensity of extending
dendrites into the airway lumen through formation of tight
junctions with bronchial epithelial cells. Immediately below,
the lamina propria of the conducting airways contains
MHCIIhiCD11chi cells that also express high levels of CD11b,
but not CD103, and are a rich source of proinﬂammatory
chemokines (Lambrecht and Hammad, 2009; Guilliams et al.,
2013; Grayson, 2006). The CD11b+CD103− subset also
expresses the signal regulatory protein-α (SIRPα) molecule.
The exact location of the CD11cint Siglec-H+ BSA-1+ pDCs in
the lung is unclear although they can be found to line alveolar
septa in situ and have been recovered from digests of large
conducting airways. The alveolar space also contains
CD11chiMHCIIhi DCs and is easily accessible by broncho
alveolar lavage.
The development of lung CD103+CD11b− cDCs depends
on Id2 and IRF8, aligning these cells with the classical
CD8α+ and CD103+ DC lineage (Edelson et al., 2010; Gin-
houx et al., 2009; Schlitzer et al., 2013). Consistent with this,
lung CD103+CD11b− cDCs are specialized in cross-pre-
sentation of antigens to CD8+ T cells. Notably, lung
CD103+CD11b− cDCs prominently express RALDH after Ag
inhalation and facilitate de novo Treg cell induction (Plan-
tinga et al., 2010). The lung CD103−CD11b+ cDCs are out-
numbered by the cross-presenting CD103+ cDCs. More
recently, CD11b+ cDCs, further deﬁned as being CD24+,
were shown to be dependent on IRF4. The CD11b+CD24+
cDCs were found to direct a Th17 cell response after chal-
lenge possibly due to their production of IL-23 (Schlitzer
et al., 2013; Kim and Lee, 2014). Fate-mapping systems
have also shown that while almost all lung CD103+ cDCs are
CDP derived, this is not the case for CD11b+ cDCs, for which
only about 50% of cells have been found to be of CDP origin
(Liu and Nussenzweig, 2010). The additional developmental
pathway for lung CD11b+ cDCs in the steady state remains
to be deﬁned.
DC in skin
The skin can be divided into two anatomical sites: the epi-
dermis and the dermis. The epidermis composed of ker-
atinocytes is a tightly packed stratiﬁed epithelium that forms
the water-impermeable stratum corneum. A basement
membrane separates the epidermis from the underlying
dermis, which is made up of ﬁbroblasts and of intertwined
collagen and elastin ﬁbers (Merad et al., 2008; Malissen
et al., 2014). The mononuclear phagocyte system is com-
posed of DCs, monocytes, and macrophages. In the skin,
DCs may include pDC, cDC, and moDC. Under steady-state
conditions, pDCs are absent from the skin. They have only
been identiﬁed in inﬂamed skin where they promote wound
repair and mediate the systemic pro-inﬂammatory response
that is seen after stimulation with Toll-like receptor 7 (TLR7)
agonists (Gregorio et al., 2010).
Mouse cDCs in the dermis are generally categorized
using the expression of CD11c and CD11b (also known as
ITGAM). Dermal CD11c+CD11b− cDCs express the C-type
lectin langerin (also known as CD207 and CLEC4K) and
include CD103+ and CD103− cells (Poulin et al., 2007;
Crozat et al., 2011). They are developmentally related to the
CD8α+ cDCs that reside in secondary lymphoid tissues
(Crozat et al., 2011; Hildner et al., 2008). Dermal CD11b+
cDCs are the most abundant type of DC in healthy dermis
and, until recently, it has been difﬁcult to distinguish them
from CD11b+ monocyte- derived DCs and macrophages.
The cDCs that are found in healthy non-lymphoid tissue,
such as the skin, are not ‘at rest’. A small proportion of these
cDCs undergoes a maturation process that is referred to as
homeostatic maturation and that involves morphological and
phenotypical changes that lead to their migration to the
draining lymph nodes (Wilson et al., 2008). Such homeo-
static maturation occurs continuously in germ-free mice and
does not require TLR signals (Wilson et al., 2008).
Following homeostatic maturation, non-lymphoid tissue
cDCs upregulate their expression of MHCII molecules and
can transport cutaneous self-antigens to the T cell zones of
the draining lymph nodes. If they encounter T cells that have
escaped central tolerance, these cDCs trigger an abortive
programme of activation in autoreactive T cells. In response
to activation by protozoal, fungal, viral or bacterial stimuli,
cDCs that reside in skin undergo a terminal differentiation
program that differs from homeostatic maturation in that it
additionally results in upregulation of the expression of co-
stimulatory molecules. Such maturation leads to the migra-
tion of cDCs to draining lymph nodes, where they promote
the clonal expansion of naïve antigen-speciﬁc Tcells and the
acquisition of T cell effector functions (Probst et al., 2003;
Spörri and Reis e Sousa, 2005).
In human dermis, during steady-state conditions, DCs are
classically divided into CD14+ and CD1a+ DCs (Nestle et al.,
2009). CD14+ dermal dendritic cells (DDC) show variable
expression of CD1a, CD1c, and CD163 (Haniffa et al.,
2009). CD14+ DDC express low levels of CD80 and CD86
and are relatively poor inducers of naïve T-cell proliferation.
They do however efﬁciently take up antigen, possibly due to
expression of c-type lectins like CD206 and CD209/DC-
SIGN (Haniffa et al., 2012; Klechevsky et al., 2008; Angel
et al., 2007; Angel et al., 2006; Nestle et al., 1994). They also
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have the ability to induce Treg through high production of
IL-10 (Chu et al., 2012). Skin-derived CD1a+ DCs in contrast
express high levels of CD80 and CD86 and strongly induce
allogeneic naïve CD4+ T cells and CD8+ T-cell proliferation
(Haniffa et al., 2012; Klechevsky et al., 2008; Angel et al.,
2007; Angel et al., 2006; Nestle et al., 1994). CD1a+ DDC
isolated from skin-draining lymph nodes were found to
preferentially induce TH2 polarization similar to LC (Segura
et al., 2012).
HUMAN DC SUBSETS IN PERIPHERAL BLOOD
In addition to the DC subsets described in different human
tissues, human blood also contains different DC subsets. All
blood DCs express high levels of HLA-DR and lack typical
lineage markers CD3 (T cell), CD19/20 (B cell), and CD56
(natural killer cell). Myeloid DCs (mDCs) express typical
myeloid antigens CD11c, CD13, CD33, and CD11b, corre-
sponding to mouse CD11c ‘classical’ or ‘conventional’ DCs.
In humans, both monocytes and mDCs express CD11c, but
DCs lack CD14 or CD16 and can be split into CD1c+ and
CD141+ subsets (Mittag et al., 2011; Jongbloed et al., 2010;
Poulin et al., 2010; Crozat et al., 2010; Bachem et al.,
2010), functionally corresponding to the mouse CD11b+ and
CD8+/CD103+ cDC, respectively (Mittag et al., 2011; Jong-
bloed et al., 2010; Poulin et al., 2010; Crozat et al., 2010;
Bachem et al., 2010). pDCs were ﬁrst identiﬁed in humans.
They typically lack myeloid antigens and can be distin-
guished by the expression of CD123, CD303, and CD304
(Cella et al., 1999; Mathan et al., 2013).
INFLAMMATORY DC
During inﬂammation or infection, lymphoid and nonlymphoid
organs can harbor DCs that originate from monocyte inﬁl-
trates and have been termed “monocyte-derived DCs”
(moDCs) or “inﬂammatory DCs”. MoDCs are phenotypically
difﬁcult to discern from cDCs because they share similar
expression patterns of MHC-II, CD11b, and CD11c. How-
ever, as an indicative of their monocyte precursor, moDCs
express CD64, the Fc-gamma receptor 1 (FcγRI) (Mildner
et al., 2013). Monocytes have long been known to give rise
to DC-like cells that can efﬁciently stimulate T cells when
cultured in vitro in the presence of GM-CSF and IL-4
(Plantinga et al., 2013). Gene expression proﬁles of cDCs
and BM culture-derived DCs differ considerably. A relation of
moDCs and cDCs is supported by the fact that culture-
derived moDCs express the transcription factor zbtb46 that
is restricted to cDCs present in the lymphoid tissues (Sat-
pathy et al., 2012). MoDCs have since been described
during pathogenic inﬂammation, experimental sterile
inﬂammation, and in models of inﬂammatory diseases, such
as colitis, rheumatoid arthritis (RA), systemic lupus
erythematosus (SLE), and experimental autoimmune
encephalomyelitis (EAE) (Ganguly et al., 2013).
THE FUNCTION OF miRNA IN THE DEVELOPMENT
OF DC
In DCs, CD11c-speciﬁc deletion of Dicer caused reduction in
Langerhans cells without obvious perturbation of other DC
subsets (Kuipers et al., 2010). However, within hematopoi-
etic cells, miRNAs are differentially expressed by different
lineages of hematopoietic cells and their precursors.
Amongst DCs, the miRNA expression patterns are also
distinct amongst different DC subsets (Kuipers et al., 2010).
It has been found that miR-22 is highly expressed in
mouse CD11c+CD11b+B220− cDCs compared to pDCs, and
is induced in DC progenitor cell cultures with GM-CSF, which
stimulates CD11c+CD11b+B220− cDCs differentiation.
Overexpression of miR-22 during DC development
enhanced CD11c+CD11b+B220− cDC generation at the
expense of pDCs, while miR-22 knockdown demonstrated
an opposite effect (Li et al., 2012). Overexpression and
knockdown of miR-22 showed signiﬁcant effects on the
mRNA abundance of IRF8, a transcription factor essential
for pDC and CD8α+ cDC development. These studies
demonstrated that miR-22 was important in regulating the
differentiation of DC subsets (Li et al., 2012).
Another important miRNA involved in DC homeostasis is
miR-142. By analyzing miRNA expression proﬁles for distinct
myeloid populations, including BM-resident progenitors,
monocytes, and mature splenic DC subsets, miR-142 was
found to be highly expressed in classic FLT3-L–dependent
CD4+ cDCs, whereas reduced expression was observed in
CD8α+ or CD4−CD8α− cDCs (Mildner et al., 2013). More-
over, mice deﬁcient for miR-142 displayed an impairment of
CD4+ cDC homeostasis both in vitro and in vivo. Compar-
ison of the expression proﬁles of WT and miR-142−/−CD4+
cDC equivalents using ingenuity pathway analysis revealed
an up-regulation of the transcription factors HoxA9, IRF8,
and Meis1 in miR-142−/−CD4+ cDCs. The up-regulation of
IRF8 may suggest a function for miR-142 in the speciﬁcation
of CD4+ versus CD8α+ cDCs through regulation of the IRF8
pathway (Mildner et al., 2013).
THE ROLE OF miRNA IN THE ACTIVATION OF DC
In addition to the role of miRNA in DC development, miRNA
also functions in DC activation. When human moDCs were
stimulated with LPS, miR-155 and several other miRNAs
were highly up-regulated. Further in vitro studies showed
that miR-155 acts as a positive regulator for the production of
several pro-inﬂammatory cytokines including IL-6, IL-23,
IL-12, and TNF-α by mouse moDCs stimulated using LPS.
MiR-155 modulates cytokine production by targeting the
negative regulators of signaling, such as SOCS1 and SHIP1
(Ceppi et al., 2009; O’Connell et al., 2009; O’Connell et al.,
2010).
MiR-146a, which can also be induced by LPS stimulation,
was found to negatively regulate DC activation. Knockdown
of miR-146a caused an increase in NF-κB signaling through
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direct targeting TRAF6 and IRAK1 (Taganov et al., 2006).
MiR-142-3p was also identiﬁed as a key negative regulator
of IL-6. In contrast to miR-155, which is strongly up-regulated
after LPS stimulation, miR-142-3p is constitutively and highly
expressed in resting moDCs but down-regulated after LPS
stimulation. MiR-142-3p directly targets IL-6 mRNA and thus
speciﬁcally affects IL-6 expression (Sun et al., 2011).
Several miRNAs have been reported to modulate IL-12
production. MiR-21 was identiﬁed to directly inhibit IL-12p35
expression. Compared to wild type mice, in vitro derived
moDCs from miR-21 deﬁcient mice had enhanced produc-
tion of IL-12, but not other cytokines (including TNF-α,
IL-6, and IL-23) upon stimulation by LPS (Lu et al.,
2011). MiR-10a also directly targets the IL-12 gene. Unlike
miR-21, miR-10a negatively regulates the production of
IL-12/IL-23p40. Ectopic expression of miR-10a in moDCs
suppressed both production of IL-12 and IL-23 (Xue et al.,
2011). Compared to miR-21 and miR-10a that directly target
IL-12 genes, some other miRNAs target the signaling com-
ponents that will affect multiple downstream targets. For
example, miR-148/152 suppressed IL-12 as well as IL-6
production; miR-23b suppressed IL-12 production while
enhancing IL-10 production (Liu et al., 2010).
Maturation of moDCs from human monocytes is accom-
panied by upregulation of DC-SIGN and downregulation of
CD14. Based on DC-SIGN/CD14 expression ratios, miR-21,
miR-34a, and their cognate targets WNT1 and JAG1 were
found to negatively inﬂuence moDC differentiation (Hashimi
et al., 2009). Similarly, inhibition of miR-511 and miR-99b
resulted in reduced DC-SIGN levels (Tserel et al., 2011).
Although the main body of current research on the role of
miRNAs in regulating DC differentiation and function used
in vitro GM-CSF differentiated DCs, several studies have
investigated other type of DCs. MiR-223 was found highly
expressed in freshly isolated epidermal LCs, and lack of
miR-223 signiﬁcantly increased LCs-mediated antigen-
speciﬁc CD8+ T cell proliferation in vivo and in vitro (Mi et al.,
2013). pDCs are specialized cells that produce type-I IFN
and express high levels of TLR7 and TLR9. Studies with
human pDCs have revealed a role for miR-155 in ﬁne tuning
the TLR7-stimulated IFN-α production. Although TLR7
induced up-regulation of both miR-155* and miR-155
through the JNK pathway in pDCs, miR-155* induced during
early phase of pDC activation enhanced IFN-α production by
suppressing IRAKM, whereas miR-155 induced during later
phase of pDC activation inhibited IFN-α expression by tar-
geting TAB2. Thus, these two miRNAs cooperatively regu-
lated the production of type-I IFN by human pDCs (Zhou
et al., 2010).
THE ROLE OF DC INTRINSIC miRNA IN
AUTOIMMUNE DISEASE
The involvement of DCs in tolerance and autoimmunity is
complex and bidirectional. Indeed, DCs may promote toler-
ance through multiple mechanisms, such as through central
and peripheral tolerance induction, the generation and
maintenance of Treg cells, as well as the induction of T cell
unresponsiveness. Conversely, the powerful antigen pre-
sentation capacity of DCs may promote the activation and/or
differentiation of self-reactive effector T cells, either because
of the defective processes of central and peripheral toler-
ance induction or inappropriate activation of the self-reactive
T cells due to impaired/ineffective negative regulation.
Increasing evidence has demonstrated that miRNAs are
important regulators for normal immune responses and
contribute to the prevention of autoimmunity (Table 1). They
exert their effects either through regulating the differentiation
and function of DCs or through direct regulation of immune
responses.
Rheumatoidarthritis (RA) isa systemicautoimmunedisorder
characterized by chronic inﬂammation of synovial tissue that
results in irreversible joint damage. Inﬂammatory cytokines,
especially TNF-α, IL-1β, and IL-6are known toplayan important
role in RA pathogenesis, as inhibition of these cytokines can
ameliorate disease in some patients (Smolen et al., 2007;
Bresnihan et al., 1998). Stanczyk et al. reported increased
miR-155 and miR-146a expression in RA synovial ﬁbroblasts
compared to those in osteoarthritis (OA) patients (Stanczyk
et al., 2008). Furthermore, miR-155 expression was higher in
RA synovial tissue compared to that ofOA.MiR-155 expression
was also higher in monocytes from RA synovial ﬂuid compared
to those from RA peripheral blood. Enhanced expression of
miR-155 in RA synovial ﬁbroblasts revealed matrix metallopro-
teinase 3 (MMP-3) as a potential target of miR-155, suggesting
that miR-155 may modulate downstream tissue damage
(Stanczyk et al., 2008). SincemiR-155 is a positive regulator for
moDC secreted IL-12p40, IL-12p35, and TNF-α (Dunand-
Sauthier et al., 2011), the increased expression of miR-155
probably facilitates the excessive inﬂammatory response.
SLE is another systemic inﬂammatory autoimmune dis-
ease characterized by the presence of autoantibodies
against numerous self-antigens including chromatin,
ribonucleoproteins, and phospholipids. Seven miRNAs
(miR-31, miR-95, miR-99a, miR-130b, miR-10a, miR-134,
and miR-146a) were expressed at 6-fold lower level in SLE
patients than that of healthy controls (Tang et al., 2009).
Among these miRNAs, miR-146a in particular has been
reported to negatively regulate the innate immune response
by targeting interleukin-1 receptor–associated kinase 1
(IRAK1) and tumor necrosis factor receptor–associated
factor 6 (TRAF6) in monocyte and moDC. Further analysis
showed that under-expression of miR-146a negatively cor-
related with clinical disease activity and the interferon (IFN)
scores in patients with SLE. Over-expression of miR-146a
reduced, whereas inhibition of endogenous miR-146a
increased, the expression of type I IFNs in peripheral blood
mononuclear cells (PBMCs) (Steinman and Cohn, 1973).
Besides, as miR-10a has also been demonstrated to nega-
tively regulate DC function by direct targeting IL-12/IL-23p40
(Xue et al., 2011), its lower expression in SLE patients may
also promote the autoimmune responses.
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MiRNAs are also likely involved in the pathogenesis of
psoriasis, a disease that may occur in association with
inﬂammatory bowel disease (IBD). In a study comparing
psoriasis patients to healthy controls, miR-203, miR-21, and
miR-146a were signiﬁcantly higher, while miR-123b was
decreased in psoriatic skin compared to patients with atopic
dermatitis and healthy controls. MiR-203 is expressed at the
highest level in skin keratinocytes. One potential target of
miR-203, SOCS-3, is upregulated in psoriatic lesions. Sup-
pression of SOCS-3 activity leads to activation of STAT3, which
when activated in keratinocytes in transgenic mice leads to the
development of psoriasis (Sonkoly et al., 2007). Interestingly, a
signiﬁcant accumulation of FLT3+CD11c+ DCs in human pso-
riatic lesions and in the skin of experimental preclinical K14-
VEGF transgenic homozygous mice, a mouse model for pso-
riasis. Targeted inhibition of FLT3 almost completely cured the
psoriasis-like disease (Yan et al., 2014). As STAT3 is the key
transcription factor for FLT3 induced DC production, the
increasedmiR-203expressionmay lead toactivationofSTAT3,
and then facilitate pDC and cDC differentiation.
As seen in RA, SLE, and psoriasis, there is increasing
data that patients with ulcerative colitis (UC) and Crohn’s
disease (CD) have altered miRNA proﬁles in involved tis-
sues compared to controls. The ﬁrst study examined miRNA
expression in IBD compared sigmoid colon biopsies from
patients with active UC, inactive UC, chronic active CD,
irritable bowel syndrome, and microscopic colitis with heal-
thy control subjects. Eight miRNAs (miR-16, miR-21,
miR-23a, miR-24, miR-29a, miR-126, miR-195, and Let-7f)
were signiﬁcantly increased in active UC tissues and three
miRNAs (miR-192, miR-375, and miR-422b) were signiﬁ-
cantly decreased in the UC tissues compared to healthy
controls (Wu et al., 2008). MiR-192 and miR-21 were the
most highly expressed miRNAs associated with active UC in
human colon tissues. MiR-21 has been demonstrated posi-
tively regulating the progression of DSS induced colitis and
miR-21 deﬁcient mice showed improved survival rate during
DSS induction (Shi et al., 2013). A second study conﬁrmed
that miR-21 was elevated in inﬂamed tissue from 12 UC
patients compared to 12 healthy controls. This study also
identiﬁed upregulated miR-155 in inﬂamed tissues (Takagi
et al., 2010). Similar to miR-21, miR-155 knockout mice
showed alleviated symptoms in DSS induced colitis model
(Singh et al., 2014). A third analysis of miRNAs in UC tissue




miR-22 IRF8 Enhances CD11c+CD11b+B220− cDC generation at the
expense of pDCs
miR-142 IRF8 Plays a pivotal role in the maintenance of CD4+ DCs
miR-142-3p IL-6 Speciﬁcally inhibits IL-6 expression by moDC MS
miR-21 IL-12p35, Wnt1 Negatively regulates the production of IL-12 by moDC;
negatively regulate the development of moDC
SLE, IBD, UC, MS




Suppress the production of IL-12 and IL-6 SLE
miR-23b Notch1, NF-κB Inhibits the production of IL-12 while promotes IL-10
production
UC
miR-155 SOCS1, SHIP1, TAB2 Positively regulates the production of several pro-
inﬂammatory cytokines including IL-6, IL-23, IL-12,
and TNF-α
RA, IBD
miR-146a IRAK1, TRAF6 Negatively regulates TLR4-NF-κB pathway in
monocytes
RA, SLE, IBD
miR-34a JAG1 Negatively regulates the development of moDC MS
miR-223 C/EBPβ Negatively regulates LCs-mediated antigen-speciﬁc
CD8+ T cell proliferation, production of inﬂammatory
cytokine TNFα, IL-1β, and IL-23 by intestinal DCs.
Positively regulates the differentiation of intestinal
CX3CR1+ macrophages
UC
miR-29 IL-12p40, ATF2 Negatively regulates the production of IL-23 production
by moDC
UC
miR-155* IRAKM Positively regulates the production of IFN-α by human
pDC
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examined eight UC patients and 10 healthy controls. Biop-
sies were obtained from inﬂamed and non-inﬂamed tissues of
UC patients. In this study, ﬁve miRNAs (miR-29a, miR-29b,
miR-126*, miR-127-3p, miR324-3p) were found upregulated
and four (miR-188-5p, miR-25, miR-320a, miR-346) down-
regulated in both quiescent and active UC compared to
healthy controls (Fasseu et al., 2010). As DCs are important
regulators for IBD, we examined miRNA expression speciﬁ-
cally in intestinal DC subsets and found that the expression of
miR-223 by intestinal DCs decreased continuously during the
progression of colitis. By using the DSS-induced colitis
mouse model, we demonstrated that miR-223 deﬁciency
resulted in more severe symptoms. Intestinal DCs in miR-223
deﬁcient mice showed a more pro-inﬂammatory phenotype
and a decreased number of CX3CR1+ regulatory macro-
phages was also observed in miR-223 deﬁcient mice.
Mechanistic study revealed that miR-223 play an important
role in maintaining the homeostasis of intestinal macro-
phages and DCs by directly targeting C/EBPβ (Zhou et al.,
2015). Although different colitis related miRNAs have been
reported, most of the expression proﬁles of these miRNAs
were obtained form the tissue or a mixture of different cell
types. In order to get a better understanding of the functions
of these miRNAs, further analysis of their changes in different
cell types is required. As one example, miR-29a was shown
to be a negative regulator for colitis by directly inhibiting the
production of IL-23 by moDCs (Brain et al., 2013), it was also
found upregulated in active UC tissues (Fasseu et al., 2010).
CONCLUSIONS
Rapid progress has been made in recent years in our under-
standing of the roles ofmiRNAs in regulating differentiation and
function of DCs. These studies have helped us to better
understand the biological signiﬁcance of these miRNAs.
Meanwhile, increasingnumbersof studieshavesuggested that
the dysregulated expression of miRNAs in DCsmay be closely
associated with different immune disorders. However, most of
the current available evidence was mainly derived from in vitro
studies with GM-CSF-differentiated DCs, the equivalents of
moDCs that become abundant during inﬂammation. It remains
to be conﬁrmedwhether these ﬁndings from in vitro studies can
be applied to in vivo settings when very dynamic interaction
between multiple types of immune cells and multiple compo-
nents of microbes occur. Furthermore, complex DC networks
consist of many DC subsets with shared and distinct functions.
It remains largely unknown how miRNAs regulate the devel-
opment and function of different DC subsets. Further studies
are required to clarify the contribution ofmiRNAs to the diversity
ofDCsubsets in lymphoid andnon-lymphoid tissues, and to the
development of DC related immune disorders.
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